ArticleNature medicine2021
Author Correction: Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease.
Open access · greenAbstract readPublished Erratum
In one paragraph
Article in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 8 citations in OpenAlex.
- Cytoskeletal Proteins and Alzheimer's Disease Pathogenesis: Focusing on the Interplay with Tau Pathology.Biomolecules · 2025Review
- Divergent disruptive effects of soluble recombinant tau assemblies on synaptic plasticity in vivo.Molecular brain · 2025Article
- Decoding the Cellular Trafficking of Prion-like Proteins in Neurodegenerative Diseases.Neuroscience bulletin · 2024Review
- Retinal Alterations Predict Early Prodromal Signs of Neurodegenerative Disease.International journal of molecular sciences · 2024Review
- Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- Rate of tau propagation is a heritable disease trait in genetically diverse mouse strains.iScience · 2023Article
- Towards a Mechanistic Model of Tau-Mediated Pathology in Tauopathies: What Can We Learn from Cell-Based In Vitro Assays?International journal of molecular sciences · 2022Review
- Biofluid Biomarkers of Alzheimer's Disease: Progress, Problems, and Perspectives.Neuroscience bulletin · 2022Review
Corrections and comments
- Erratum for
Authors and funding
27 authors at 4 institutions in 1 country.
Simon DujardinAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.ORCID http://orcid.org/0000-0002-5614-341X
Caitlin ComminsAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Aurelien LathuiliereAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Pieter BeerepootHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3721-3213
Analiese R FernandesAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Tarun V KamathAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Mark B De Los SantosAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.ORCID http://orcid.org/0000-0002-7195-5141
Naomi KlicksteinAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Diana L CorjucAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Bianca T CorjucAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Patrick M DooleyAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Arthur ViodeHarvard Medical School, Boston, MA, USA.
Derek H OakleyAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Benjamin D MooreAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Kristina MullinGenetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Dinorah Jean-GillesDepartment of Neuroscience, Merck & Co., Boston, MA, USA.
Ryan ClarkDepartment of Neuroscience, Merck & Co., Boston, MA, USA.
Kevin AtchisonDepartment of Neuroscience, Merck & Co., Boston, MA, USA.
Renee MooreDepartment of Neuroscience, Merck & Co., Boston, MA, USA.
Lori B ChibnikAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Rudolph E TanziHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7032-1454
Matthew P FroschHarvard Medical School, Boston, MA, USA.
Alberto Serrano-PozoAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.ORCID http://orcid.org/0000-0003-0899-7530
Fiona ElwoodDepartment of Neuroscience, Merck & Co., Boston, MA, USA.
Judith A SteenHarvard Medical School, Boston, MA, USA.
Matthew E KennedyDepartment of Neuroscience, Merck & Co., Boston, MA, USA.
Bradley T HymanAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA. bhyman@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-7959-9401
Harvard University · USMassachusetts General Hospital · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USBoston Children's Hospital · US
Funding
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Sudeshna Das · 2019 to 2026
$36.5MAre multiple tau species toxic in Alzheimer's Disease?RF1AG059789 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 2018 to 2018
$2.7MSynergy between amyloid and tau in Alzheimer's DiseaseRF1AG058674 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 2018 to 2018
$2.6MAstrocyte Reaction in Alzheimer's DiseaseK08AG064039 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI SERRANO-POZO, ALBERTO · 2019 to 2023
$837kComplexity and Heterogeneity of Alzheimer diseaseR56AG061196 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 2019 to 2019
$654kAlzheimer's Association 2018-AARF-591935NIA NIH HHS K08 AG064039NIA NIH HHS P30 AG062421NIA NIH HHS R56 AG061196NIA NIH HHS RF1 AG058674NIA NIH HHS RF1 AG059789Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) P2ELP3_184403U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) 1K08AG064039U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) 1P30AG062421U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) 1RF1AG058674U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) 1RF1AG059789
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.